Am J Psychiatry 159:255-262, February 2002
© 2002 American Psychiatric Association
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Jan Volavka, M.D., Ph.D.,
Pal Czobor, Ph.D.,
Brian Sheitman, M.D.,
Jean-Pierre Lindenmayer, M.D.,
Leslie Citrome, M.D., M.P.H.,
Joseph P. McEvoy, M.D.,
Thomas B. Cooper, M.A.,
Miranda Chakos, M.D., and
Jeffrey A. Lieberman, M.D.
OBJECTIVE: The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. METHOD: In a double-blind trial, 157 inpatients with a history of suboptimal treatment response were randomly assigned to treatment with clozapine, olanzapine, risperidone, or haloperidol for 14 weeks (an 8-week escalation and fixed-dose period followed by a 6-week variable-dose period). RESULTS: Clozapine, risperidone, and olanzapine (but not haloperidol) resulted in statistically significant improvements in total score on the Positive and Negative Syndrome Scale. Improvements seen in total and negative symptom scores with clozapine and olanzapine were superior to haloperidol. The atypical drugs, particularly olanzapine and clozapine, were associated with weight gain. CONCLUSIONS: The effects of atypical antipsychotics in this population were statistically significant but clinically modest. The overall pattern of results suggests that clozapine and olanzapine have similar general antipsychotic efficacy and that risperidone may be somewhat less effective. Clozapine was the most effective treatment for negative symptoms. However, the differences among treatments were small.
This article has been cited by other articles:
|
|
|
|
 
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
July 1, 2009;
35(4):
775 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Fiedorowicz, D. A. Solomon, J. Endicott, A. C. Leon, C. Li, J. P. Rice, and W. H. Coryell
Manic/Hypomanic Symptom Burden and Cardiovascular Mortality in Bipolar Disorder
Psychosom Med,
July 1, 2009;
71(6):
598 - 606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Patnaik, M. J. Renda, M. C. Athanasiou, and C. R. Reed
The Role of Pharmacogenetics in Treating Central Nervous System Disorders
Experimental Biology and Medicine,
December 1, 2008;
233(12):
1504 - 1509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Shekhar, W. Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F. P. Bymaster, D. L. McKinzie, and C. C. Felder
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Am J Psychiatry,
August 1, 2008;
165(8):
1033 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Lang, M. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke, and S M. Tugtekin
Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives
J Psychopharmacol,
July 1, 2008;
22(5):
576 - 580.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. W. Swanson, M. S. Swartz, R. A. Van Dorn, J. Volavka, J. Monahan, T. S. Stroup, J. P. McEvoy, H. R. Wagner, E. B. Elbogen, J. A. Lieberman, et al.
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
The British Journal of Psychiatry,
July 1, 2008;
193(1):
37 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Focus,
April 1, 2008;
6(2):
212 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Spiegel, D. P. Casella, D. M. Callender, and N. Dhadwal
Treatment of Akinetic Mutism with Intramuscular Olanzapine: A Case Series
J Neuropsychiatry Clin Neurosci,
February 1, 2008;
20(1):
93 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-K. Fang, H.-W. Chen, S.-I. Liu, C.-J. Lin, L.-Y. Tsai, and Y.-L. Lai
Prevalence, Detection and Treatment of Delirium in Terminal Cancer Inpatients: A Prospective Survey
Jpn. J. Clin. Oncol.,
January 31, 2008;
(2008)
hym155v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Psychiatr Serv,
July 1, 2007;
58(7):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bleakley, O. Olofinjana, and D. Taylor
Which antipsychotics would mental health professionals take themselves?
Psychiatr. Bull.,
March 1, 2007;
31(3):
94 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents
J Psychopharmacol,
November 1, 2006;
20(6_suppl):
6 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Hoptman, J. Volavka, P. Czobor, G. Gerig, M. Chakos, J. Blocher, L. L. Citrome, B. Sheitman, J.-P. Lindenmayer, J. A. Lieberman, et al.
Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder
J Neuropsychiatry Clin Neurosci,
November 1, 2006;
18(4):
509 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Nasrallah and R. Lasser
Improving patient outcomes in schizophrenia: achieving remission
J Psychopharmacol,
November 1, 2006;
20(6_suppl):
57 - 61.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Shaw, A. Sporn, N. Gogtay, G. P. Overman, D. Greenstein, P. Gochman, J. W. Tossell, M. Lenane, and J. L. Rapoport
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison.
Arch Gen Psychiatry,
July 1, 2006;
63(7):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. McEvoy, J. A. Lieberman, T. S. Stroup, S. M. Davis, H. Y. Meltzer, R. A. Rosenheck, M. S. Swartz, D. O. Perkins, R. S.E. Keefe, C. E. Davis, et al.
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Am J Psychiatry,
April 1, 2006;
163(4):
600 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Am J Psychiatry,
February 1, 2006;
163(2):
185 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Breier, P. H. Berg, J. H. Thakore, D. Naber, W. F. Gattaz, P. Cavazzoni, D. J. Walker, S. M. Roychowdhury, and J. M. Kane
Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2005;
162(10):
1879 - 1887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Psychiatr Serv,
January 1, 2005;
56(1):
85 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, M. P. Ball, E. Weiner, B. Kirkpatrick, J. M. Gold, R. P. McMahon, and W. T. Carpenter Jr.
Olanzapine Treatment of Residual Positive and Negative Symptoms
Am J Psychiatry,
January 1, 2005;
162(1):
124 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Akhtar, C. Kelly, A. Gallagher, and J. R Petrie
Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk
The British Journal of Diabetes & Vascular Disease,
September 1, 2004;
4(5):
303 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. McD. YOUNG, B. R. LAWFORD, M. BARNES, S. C. BURTON, T. RITCHIE, W. K. WARD, and E. P. NOBLE
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele
The British Journal of Psychiatry,
August 1, 2004;
185(2):
147 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Herbeck, J. C. West, I. Ruditis, F. F. Duffy, D. J. Fitek, C. C. Bell, and L. R. Snowden
Variations in Use of Second-Generation Antipsychotic Medication by Race Among Adult Psychiatric Patients
Psychiatr Serv,
June 1, 2004;
55(6):
677 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Volavka and L. Citrome
Olanzapine vs Haloperidol for Treatment of Schizophrenia
JAMA,
March 3, 2004;
291(9):
1064 - 1064.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rosenheck, D. Perlick, S. Bingham, and J. Collins
Olanzapine vs Haloperidol for Treatment of Schizophrenia--Reply
JAMA,
March 3, 2004;
291(9):
1065 - 1066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Opolka, K. L. Rascati, C. M. Brown, and P. J. Gibson
Ethnicity and Prescription Patterns for Haloperidol, Risperidone, and Olanzapine
Psychiatr Serv,
February 1, 2004;
55(2):
151 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Focus,
January 1, 2004;
2(1):
59 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G Liu, S. X Sun, D. B Christensen, and X. Luo
Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia
Ann. Pharmacother.,
January 1, 2004;
38(1):
134 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sur, P. J. Mallorga, M. Wittmann, M. A. Jacobson, D. Pascarella, J. B. Williams, P. E. Brandish, D. J. Pettibone, E. M. Scolnick, and P. J. Conn
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity
PNAS,
November 11, 2003;
100(23):
13674 - 13679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman
Schizophrenia
N. Engl. J. Med.,
October 30, 2003;
349(18):
1738 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Santarlasci and A. Messori
Clinical Trial Response and Dropout Rates with Olanzapine Versus Risperidone
Ann. Pharmacother.,
April 1, 2003;
37(4):
556 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. DURHAM, M. GUTHRIE, R. V. MORTON, D. A. REID, L. R. TRELIVING, D. FOWLER, and R. R. MACDONALD
Tayside--Fife clinical trial of cognitive--behavioural therapy for medication-resistant psychotic symptoms: Results to 3-month follow-up
The British Journal of Psychiatry,
April 1, 2003;
182(4):
303 - 311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. MEIBACH
Comparative Effectiveness of Antipsychotic Drugs
Am J Psychiatry,
March 1, 2003;
160(3):
589 - 590.
[Full Text]
|
|
|
|
|
|
|
J.-P. Lindenmayer, P. Czobor, J. Volavka, L. Citrome, B. Sheitman, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Am J Psychiatry,
February 1, 2003;
160(2):
290 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. BILDER, J. VOLAVKA, L. CITROME, P. CZOBOR, M. HOPTMAN, M. CHAKOS, J. P. McEVOY, T. B. COOPER, and J. A. LIEBERMAN
Dr. Bilder and Colleagues Reply
Am J Psychiatry,
December 1, 2002;
159(12):
2118 - 2119.
[Full Text]
|
|
|
|
|
|
|
R. M. Bilder, R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. McEvoy, M. Kunz, et al.
Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
June 1, 2002;
159(6):
1018 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Curtin, S. L. P. Stalman, J. Lieberman, S. Stroup, L. Schneider, J. G. Csernansky, and R. Mahmoud
Prevention of Relapse in Schizophrenia
N. Engl. J. Med.,
May 2, 2002;
346(18):
1412 - 1413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Stevens
Schizophrenia: Reproductive Hormones and the Brain
Am J Psychiatry,
May 1, 2002;
159(5):
713 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
How Effective Are Atypical Antipsychotics?
Journal Watch Psychiatry,
March 21, 2002;
2002(321):
7 - 7.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
